IFNAR1 Protein, Cynomolgus (HEK293, His)

IFNAR1, one of the subunit of IFN-α/β receptor, is a type I IFN receptor. IFNAR1 forms the heterodimeric receptor with IFNAR2. IFNAR1 mediates IFN-induced STAT signaling by interacting with tyrosine kinase 2 (Tyk2)^[1][2]. Upon activation by these IFNs, IFNAR1 and IFNAR2 undergo a conformational change to promote a cascade of downstream signaling events, including the phosphorylation of Tyk2 and JAK1, STAT1 and STAT2^[3]. IFNAR1 Protein, Cynomolgus (HEK293, His) is a recombinant Cynomolgus IFNAR1 (A25-K437) with C-terminal 6*His tag, which is produced in HEK293 cells.

IFNAR1, one of the subunit of IFN-α/β receptor, is a type I IFN receptor. IFNAR1 is expressed on peripheral blood B cells and monocytes, and mediates differentiation and activation of these cells^[4].
IFNAR1 forms the heterodimeric receptor (IFN-α/β receptor) together with IFNAR2. IFNAR1 interacts with tyrosine kinase 2 (Tyk2), and the interaction is able to stabilize IFNAR1 on the plasma membrane^[1]. Besides, IFNAR1 associates with TYK2 and initiates type I IFN-induced STAT signaling, but the activation needs IFNAR2 as a platform^[2]. IFN-α/-β can induce association of the IFNAR1 and IFNAR2, which makes JAK1 and TYK2 form a functional signaling unit^[1]. Upon activation by these IFNs, IFNAR1 and IFNAR2 undergo a conformational change to promote a cascade of downstream signaling events. The signaling events includes the phosphorylation of Tyk2 and JAK1, the signal transducers and activators of transcription STAT1 and STAT2, and the formation of the IFN-stimulated gene factor 3 (ISGF3) complex which consists of phosphorylated STAT1 and STAT2 and IRF9^[3].
The sequence of amino acids in IFNAR1 differs in different species. Human IFNAR1 shares <50% aa sequence identity with mouse.
IFNAR1 mediates IFN-induced STAT signaling by interacting with tyrosine kinase 2 (Tyk2)^[1].

Cynomolgus

HEK293

C-6*His

XP_005548864 (A25-K437)

101926190  [NCBI]

AGGKNLKSPQKVEVDVIDDNFILRWNRSEESVGNVTFSFDYQKPEMDNWIKLPGCQNMTSTKCNFSSLKLNIYDEIKLRIRAEKENTSSWCEVDSFTPFRKAQIGPPEVHLEAEDKAIVIYISPPGTEDSVMWALDRSSFTYSLVIWKNSSSVEERIENIYSRHKISKLSPETTYCLKVKAALLTSRKIGVYGPVHCIKTTVENELPPPENIEVIVQNQNYVLKWDYTYANMTFQVQWLHAFLKRKPGNHLYKWKQIPDCENVTTTQCVFPPNTFQKGIYLLRVQASDGNNTSFWSEEIKFDTEIQASLLPPVFNIRSLSDSLHISIGAPKWSENKPVIQDYPLIYEILFWENTSKAERKIIKKKTDVTIPNLKPLTVYCVKARAHSMDEKLNKSSVFSDVVCEETKSGNTSK

70-102 kDa

Greater than 95% as determined by reducing SDS-PAGE.

Lyophilized powder.

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US;may vary elsewhere.

• [1]. Zanin N, et al. Interferon Receptor Trafficking and Signaling: Journey to the Cross Roads. Front Immunol. 2021 Jan 20;11:615603.  [Content Brief]

  [2]. Shemesh M, et al. IFNAR1 and IFNAR2 play distinct roles in initiating type I interferon-induced JAK-STAT signaling and activating STATs. Sci Signal. 2021 Nov 23;14(710):eabe4627.  [Content Brief]

  [3]. Jun Zou, et al. Chapter 7 - Antiviral Immunity: Origin and Evolution in Vertebrates. The Evolution of the Immune System. 2016,Pages 173-204.

  [4]. Pogue SL, et al. The receptor for type I IFNs is highly expressed on peripheral blood B cells and monocytes and mediates a distinct profile of differentiation and activation of these cells. J Interferon Cytokine Res. 2004 Feb;24(2):131-9.  [Content Brief]